TURKISH JOURNAL OF ONCOLOGY 2017 , Vol 32 , Num 4
Dermatofibrosarcoma Protuberans: A Rare Malignancy
Ümmügül ÜYETÜRK1,Tuba TASLAMACIOĞLU DUMAN2,Selma ERDOĞAN DÜZCÜ3,Nadire KÜÇÜKÖZTAŞ1,Fahri YILMAZ3
1Department of Medical Oncology, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey
2Department of Internal Medicine, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey
3Department of Pathology, Abant Izzet Baysal University, Faculty of Medicine, Bolu, Turkey
DOI : 10.5505/tjo.2017.1635 OBJECTIVE
Dermatofibrosarcoma protuberans (DFSP) is a fibrohistiocytic tumor characterized by protuberant growth pattern of skin and subcutaneous tissue. The annual incidence is 4.2 per million. It is often seen between the ages of 20?50 years. This study aimed to evaluate the characteristics of patients with DFSP.

METHODS
Patients who visited our clinic were retrospectively evaluated.

RESULTS
All patients were females and the median age was 42 (29?60) years. The evaluated tumor sites were observed in the body/trunk in one patient, at the hip in two, and at the proximal lower extremity in two. Surgical excision was done in all of them as initial treatment. Re-excision was needed in three patients. One of the patients underwent punch biopsy for diagnosis and surgical removal of the tumor with a negative surgical margin. One of the patients underwent radiotherapy. The median follow-up time was 10 (6?26) months. During the median follow-up, there was no local recurrence or metastasis.

CONCLUSION
As initial treatment, it is important to surgically remove tumors that had no distant metastasis. Positive or near surgical margins should be resected again. If a negative surgical margin cannot be achieved, radiotherapy should be used as the treatment. Imatinib mesylate is used for treatment in unresectable, recurrent, and/or metastatic tumors. Keywords : Dermatofibrosarcoma protuberans; imatinib; radiotherapy; surgery